Tissue Regenix Share Discussion Threads

[pj84] 13/4/2023 10:25

It is up marginally on September from £110m to £112m



Investment summary: TRX has a broad portfolio of innovative regenerative products that are in demand from surgeons. Completion of Phase 1 of its capacity expansion programme and reorganisation of the whole facility have led to operating efficiencies and comfort of supply to distribution partners. In our opinion, TRX is well-positioned to deliver persistently strong sales growth, which will drive margin expansion and highlight the low rating of the shares. An EV/sales multiple of 4x 2023E sales generates a valuation of $122m/£110m.

[pj84] 13/4/2023 10:21

Ok note you are comparing to September not last April.

[pj84] 13/4/2023 10:19

Not sure that is correct as the valuation Hardman put on it this year is £112m and last year it was £20m less at £92m.



Investment summary: TRX has a broad portfolio of innovative regenerative products that are in demand from surgeons. Completion of Phase 1 of its capacity expansion programme has comforted distribution partners and provided positive momentum. We believe TRX is well-positioned to deliver strong sales growth, which will drive margin expansion and highlight the low rating of the shares. An EV/sales multiple of 4x 2023E sales generates a valuation of $120m/£92m.

[daz] 13/4/2023 09:12

Hardman have downgraded, if you compare the 2023 and 2024 forecasts in the above to the note issued in September, so may explain why the shares have been weak of late

[pj84] 12/4/2023 21:24

Investment summary: Turning EBITDA-positive in 4Q’22 was a major milestone, and the leverage effect of expected sales growth in 2023 will become more apparent, highlighting the low rating on the shares. An EV/sales multiple of 4x 2024E sales generates a valuation of $139m/£112m. The board is proposing a 1-for-100 share consolidation to make the shares less unwieldy and to increase their attractiveness to investors.

[bomber13] 11/4/2023 15:58

There is a 16 page research note out from Hardman FYI with an inferred valuation of nearly 3 times the current market capitalisation .

[pj84] 05/4/2023 15:57

Clearly a senior moment, not sure why I thought it was 56p should have remembered I have 2 million shares definitely not worth over £1m!

[contact2fsnetcouk] 05/4/2023 15:27

Just under £8k

(one million four hundred thousand shares) 1,400,000 shares x 1p = £14,000

£14,000 x .56 of 1p = £7,840

[tnt99] 05/4/2023 15:13

Think that's around 80000 pounds still a good amount and shows things are going well

[bridggar] 05/4/2023 10:04

You are missing something.

[pj84] 05/4/2023 09:47

Unless I am misreading that RNS, then purchases of over 1.4 million shares each costing over £800k each doesn't look like just buying a few shares or being less than a months salary!

As I say unless I am missing something that is a very strong vote of confidence.

[sos100] 05/4/2023 06:17

you really need find some other share😉

[clocktower] 05/4/2023 06:16

A little vote of confidence from the ceo and cfo buying a few shares, I cannot remember what their salaries are but guessing it’s less than a months salary, so seeing how it has slid since they announced the consolidation and sprouted the nonsense about making it more liquid, I guess they want to try to demonstrate that the shares are cheap.

Great place to invest is China right now, and did they not mention the potential for the products there, maybe I am mistaken and if so please correct me, as I could have confused them with another company.

[theaviator] 04/4/2023 15:06

Sres another on floor floor. Don't say I didn't mention it. Dyor & GL

[emeraldzebra] 30/3/2023 10:49

Yep. Directors buying in excess of this level a while back enough
For me ! Let’s hope anyway.

[mickhay3] 30/3/2023 07:38

Opportunity here for all those who still need to agv down Richard is still buying.I say follow the money

[mickhay3] 29/3/2023 11:15

Trx looking a little better on the weekly chart https://ibb.co/cvyJDTs

[tnt99] 29/3/2023 07:49

Didn't expect a retrenchment and why are the brokers predicting breakeven this year I thought the expansion into China and the increased operation scene in Europe Uk and the states should point to another 25 percent increase in turnover Maybe the 1 for 100 shares comment spooked some holders

[clocktower] 29/3/2023 07:41

Liquidity drying up as Pi's pull out it seems to me with volumes likely to drop further. They will need to take mega steps forward to get the share price back to the point of near breakthrough at 0.70 impo.

[clocktower] 28/3/2023 14:18

I have invested and also traded this stock over a long period of time SOS100 - so hardly a find for me - yes my monitor is also looking very red at present, but I do not short stocks now, even though I should do so to profit from the trends and news, although I must admit from time to time in the past, I have borrowed stocks through my broker to sell short.

Trouble is companies do these sort of things before they become profitable and often look to raise funds after doing so, to go on a jolly of expansion, on the basis it will grow quickly but more often than not, it just extends the lifestyle of the directors and they increase their incomes along the way and shareholders suffer.

Prove themselves first - see the share price at 2p plus then consolidate if they can show they can deliver.

[sos100] 27/3/2023 15:11

so many stocks on down trend at the moment and you think your doing a grand job having found this one😂

[clocktower] 27/3/2023 15:04

The chart is not looking good either is it ?

Once consolidated I expect it to slide further as liquidity drys up.

I could understand it if they had already turned to a profitable business and if the share price was over 2p with a strong forward statement but not now.

You may harp on how good this is but the facts of the slide in share price speaks volumes.

I will even revise my target down now.

[ultrasilva] 27/3/2023 10:14

their broker finnCap, 21 March 2023:
hxxps://www.finncap.com/research-portal#/portal/finncap

"TISSUE REGENIX (TRX): CORP FY 2022 – a pivotal year to a sustainably profitable business Tissue Regenix reported full-year results to 31 December in line with its January trading update that indicated it had reached EBITDA profitability in Q4. What was undisclosed then was that it included a $0.45m provision, without which it would have generated an adjusted EBITDA of c.$0.4m in H2, illustrating the positive underlying progression to a profitable and sustainable growth company. The outlook remains positive – new products, new geographies and additional distributors/strategic partners fuelling growth; the differentiated nature of its products driving increased market share gains. We leave forecasts unchanged and reiterate our target price of 1.2p, at which level the stock would trade on 2023E EV/Sales of 3.6x, dropping to 3.1x in FY 2024, which we believe reflects the above-market revenue growth (2-year CAGR of 18%) and value within the business. We consider the proposal for a 1-for-100 share consolidation as appropriate for a company of its size, and will adjust our model accordingly once approved by shareholders. "

[timmy40] 24/3/2023 13:48

There are not many companies on AIM whose shares are priced at a fraction of a penny, certainly those wanting to be taken seriously by market institutions, rather than just punters.It's an easy win for management to get the share price higher and more marketable. They are ambitious and want to grow this company, i.e. The 4 S strategy ! All v positive.I'm sure management has been guided by the nominated broker/advisor to undertake this consolidation and would have spoken with the largest shareholders who have approved it too!It still needs approval at the AGM, but the management is doing a good job and should be trusted imo.

[clocktower] 24/3/2023 12:57

When companies start sprouting nonsense about consolidation providing more liquidity and reducing the spread - knowing it to not to be the case, unless it was a massive company that is traded in huge volume on a daily basis, rather than a tiddler AIM company that a lot of small traders use, that always trades between the bid and offer in a narrow range in most cases, it becomes clear where this is likely to go and also opens the door to raise money more easily for an acquisition to tack on to a slow growth business.

Will they really make a profit in FY23?